Use of denosumab in recurrent giant cell tumour of bone: Report of two cases

Yuva Chandan Reddy J, Sai Kishore VVCh, Rao AS, Satish Rao I

Pdf Page Numbers :- 29-34

Yuva Chandan Reddy J^1,*, Sai Kishore VVCh¹, Rao AS¹ and Satish Rao I²

¹Department of Orthopaedics, Krishna Institute of Medical Sciences, Minister Road, Secunderabad-500003, Telangana, India

²Department of Pathology, Krishna Institute of Medical Sciences, Minister Road, Secunderabad-500003, Telangana, India

*Corresponding author: Yuva Chandan Reddy J, Department of Orthopaedics, Krishna Institute of Medical Sciences, Minister Road, Secunderabad-500003, Telangana, India. Mobile: +91 9985458505; Email: yuvachandan@gmail.com

Received 02 November 2019; Revised 16 December 2019; Accepted 21 December 2019; Published 30 December 2019

Citation: Reddy JYC, Kishore SVVCh, Rao AS, Rao SI. Use of denosumab in recurrent giant cell tumour of bone: Report of two cases. J Med Sci Res. 2020; 8(1):29-34. DOI: http://dx.doi.org/10.17727/JMSR.2020/8-5

Copyright: © 2020 Reddy JYC et al. Published by KIMS Foundation and Research Center. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

PDF

Abstract

Giant cell tumour of bone (GCTB) is a locally aggressive benign bone tumour. Though surgery is the mainstay of treatment, recurrence rate is 8% even after extended curettage. Recurettage does not guarantee no recurrence of the tumour. The RANKL-RANK interaction, which leads to the differentiation and functioning of the osteoclast like giant cells are responsible for the osteolytic activity of tumour. Denosumab a RANK ligand inhibitor can be used in recurrent GCTB. We report two cases, where denosumab was used in recurrent GCTB with encouraging results.

Keywords: Recurrent; giant cell tumour of bone; denosumab